Ever heard of Marc Beer? Why is he popular in the biotechnology, pharmaceutical, and diagnostic industries? He is one of the most celebrated men around the world for his outstanding achievements. Marc Beer is the Co-founder, Chairman, and CEO of Renovia Inc., a pharmaceutical company that develops diagnostic and therapeutic devices. The firm also focuses on treatment to fight various pelvic floor disorders in women.
Achievements as the CEO of Renovia
Thanks to his vast experience and leadership skills, the exceptional CEO has been able to transform Renovia from a lean startup into a force to reckon with in the pharmaceutical world. He has also helped his company find investors and raise millions. For instance, Marc Beer recently helped Renovia obtain more than 42 million from investors. According to Marc, this money will be used solely in developing devices and treatments that will help the healthcare sector fight urinary incontinence, a medical problem that affects more than 250 million women around the world.
Marc Beer has also helped his company attract leading investors in the healthcare sector such as the Longwood Fund, Nova Strategic Investments, OSF Ventures, Cormorant Asset Management, and Western Technology Investment. The exceptional CEO has also helped the company develop and launch its first product, Leva, which received approval from the FDA in April 2018.
His Early Life Before Renovia
Marc Beer has over 25 years in the biotechnology, pharmaceutical, and diagnostic industries. His career journey started at Abbott Laboratories, where he held a variety of sales and marketing roles. He moved on to join Genzyme, where he became the Vice President of Global Marketing. As Vice President, Marc helped Genzyme come up with unique products and marketing strategies that helped it penetrate more regions and crash any competition that came its way.
In 2000, he founded ViaCell, a biotechnology organization that specializes in the collection, preservation, and development of umbilical cord blood stem cells. Within a few years, Beer was able to move ViaCell from a simple startup to a renowned, robust enterprise with branches all over the country.
The demand for ViaCell’s products and services led to the creation of jobs for more than 300 people. In 2005, ViaCell went public and raised more than $68 million. In 2007, Marc sold ViaCell PerkinElmer Inc. It is now listed on NYSE as PKI. Marc Beer is also part of the team that came up with Good Start, a biotechnology firm, which was acquired by InVitae. He serves as Good Start’s Chairman of the Board. He is also the Chairman of the Compensation Committee and one of the audit committee members of NASDAQ: NERV (Minerva Neurosciences). Marc is also a former a member of the Notre Dame Research. Apart from entrepreneurship, Marc is also passionate about education. Learn more: https://renoviainc.com/leadership/